Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Progressing Trials For Oral Asthma Therapy In India

Executive Summary

Novartis is advancing studies with its experimental asthma therapy fevipiprant in India, amid significant expectations around its possible impact on market dynamics including aspects such as the potentially shared patient pool with certain biologics.


Related Content

Nucala Among Flurry Of New Respiratory Products On Indian Horizon
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts